price month
initi outperform target price
target oncolog opportun mirati hold sever promis
asset signific highly-specif inhibitor
kra protein mutat common multipl
cancer one compet drug clinic develop competit
landscap substanti believ potenti success
primari driver stock strong perform year far
lead asset sitravatinib checkpoint-refractori non-smal cell lung
cancer nsclc sizabl popul current standard care
initi coverag outperform rate target price
sitravatinib provid solid base valuat kra platform
provid meaning upsid potenti mirati plan initi phase
clinic trial sitravatinib nsclc initi interim analysi
plan late limit sitravatinib impact share year
model peak annual unadjust revenu ascrib
valu estim kra market opportun global
one competitor thu far second agent
larger potenti market soon enter clinic see program
offer substanti long-term valu upsid ascrib valu
catalyst center around kra believ key catalyst
initi clinic proof-of-concept data kra program
similar data sole competitor like drive share
near term multipl readout addit sitravatinib indic
beigen collabor could add increment valu estim
valuation/risk dcf-deriv tp driven success
probabl success sitravatinib nsclc
addit valu repres potenti risk thesi includ
clinic trial delay/failur success/failur competitor financ
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mirati clinical-stag biotechnolog compani
dedic advanc novel therapeut extend live
patient directli address genet immunolog
driver cancer
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario valu per share reflect po
sitravatinib lung
grey sky scenario valu per share reflect po
sitravatinib lung po kra program
 close
initi outperform target price view interest
promis opportun offer mirati kra program even earli stage
develop believ potenti success program push
share outperform biotech index xbi biotech ralli
think still room run clinic data present later year
develop kra protein inhibitor provid potenti substanti valu
creation kra gene control cell prolifer mutat gene caus
cell continu prolifer result cancer cancer develop
known mutat kra mutat frequent oncogen
solid tumor howev due lack bind pocket kra remain difficult
target drug design mirati first compani bring clinic drug
target kra mean low competit environ larg patient
popul thu clinic success drive substanti valu base preval
mutat kra valu compar target therapi see
kra potenti opportun global
limit data mirati present date primari asset appear
highli efficaci inhibitor kra specif mutat present
patient non-smal cell lung cancer nsclc colorect cancer
pancreat cancer expect present data preclin
clinic compound earlier mirati year expect
share would trend posit news serv proof
concept strategi target kra mutant tumor
believ like use second-lin therapi nsclc
area substanti unmet need current standard care expect
would like use frontlin pancreat colorect cancer though lower
preval cancer would limit contribut overal usag
current model unadjust peak sale
mirati also develop second kra agent target mutat
present mani patient highlight untap potenti
target mutat mirati expect select molecul preclin program
later year
mirati lead asset sitravatinib also repres potenti first-to-market
opportun checkpoint inhibitor-refractori lung cancer area true
standard care exist keytruda merck plu platinum-bas chemotherapi
wide use front-lin therapi compani initi first phase trial
sitravatinib plu opdivo bristol-my first interim analysi data
plan end base initi efficaci data suggest durabl clinic
benefit improv surviv rate believ sitravatinib combin
good chanc success primari endpoint overal surviv os estim
end gain regulatori approv consid expect doctor
spoken greater-than-anticip overal respons rate orr
docetaxel compar orr report phase ii trial less confid
combo abil show statistically-improv orr interim analysi
lower expect success interim analysi delay forecast
month os readout reduc market penetr even factor
delay see sitravatinib solid foundat mirati event kra program
fail unadjust peak sale
credit suiss biotech short-term outlook like see data
see preclin data competitor
march clinic data june expect trade
evid drug viabl clinic profil bar overwhelmingli
posit neg data suggest either best-in-class potenti
failur success target kra respect
credit suiss biotech long-term outlook expect first look preclin
clinic data primari mover share expect
data support advanc registr expans arm
efficaci without unexpect toxic drive share substanti
credit suiss biotech outlook earli success kra program may
make attract oncolog target follow loxo ignyta ariad
valuat model cash flow sitravatinib
anticip loss exclus follow expir composit matter patent
expir plu assum grant standard hatch-waxman five-year
extens peak unadjust sale model cash flow
anticip loss exclus peak unadjust sale
current expect launch commerci year prior
patent expir anticip extens grant hatch-waxman
estim total revenu compound-annual-growth-rate
target price determin take split product-bas
revenu dcf valuat dcf-deriv valu repres potenti
dcf model base discount rate product
fulli dilut share million long-term oper margin tax rate
probability-adjust model assign valu sitravatinib valu
kra program assign valu pipelin revenu
risk risk thesi includ emerg previous unseen safeti issu
sitravatinib failur kra asset establish proof-of-concept
failur sitravatinib establish proof-of-concept addit indic stronger-than-
anticip competitor data neg regulatori decis
demonstr consist efficaci overal
respons rate orr initi trial compani abl
identifi promis target companion molecul also
show promis data clinic next year
initi find phase trial show efficaci
rate level expect doctor safeti
durabl signal ad
doubt abil success target kra
earli data mirati suggest highli potent efficaci inhibitor specif kra bear mutat
rais confid viabl drug target larg market one realist competitor point base
data seen mirati compar target therapi confid show respons rate
least minimum level expert look lack off-target effect owe high specif
kra specif cystein moieti consid target therapi oncolog past sever year acquisit
premium anticip substanti investor interest potenti early-stag takeout could infus valu
ii sitravatinib efficaci nsclc
sitravatinib plu opdivo exce orr
observ phase ii studi easili beat docetaxel
compar arm fall one first
option refractori set sitravatinib see rapid
uptak second-lin set nsclc establish solid
respons sitravatinib nsclc lower seen
phase ii respons compar docetaxel arm
surpris upsid suggest recent retrospect
account report clinician lead sitravatinib fail
meet primari outcom orr interim analysi delay
potenti fda review least year eras mirati time
advantag time success overal surviv achiev
concern sitravatinib confirm respons rate phase ii potenti docetaxel outperform
histor orr set result doubt sitravatinib show orr statist better
docetaxel interim analysi consider diseas control rate dcr mirati report date number patient
experienc stabl diseas keep us confid drug clear clinic benefit succeed overal surviv os
expect eventu approv later date interim time-point would provid would remov first-mov
advantag mirati mani vari asset includ multi-tki novel immunotherapi current evalu
set
sitravatinib show impress efficaci data multipl proof-of-
concept studi addit tumor particularli bladder
neoadjuv renal head neck tumor addit
beigen collabor reveal posit sign addit
tumor type provid mirati multipl path forward
sitravatinib fail show impress data proof-of-concept
studi ad doubt whether abl beat salvag
chemotherapi multipl tumor line addit beigen
studi provid convinc data tislelizumab afford
combin efficaci opdivo
believ sitravatinib demonstr clinic benefit potenti use set multipl
tumor earli stage studi feel natur assum succeed better other
current includ bladder neoadjuv renal cancer model probabl success po
take wait-and-se approach head neck mutat beigen collabor
figur stock price analysi reveal histori down
charl martineau univers toronto figur outperform past year
acquir
preclin data
initi phase trial sitravatinib
clinic data
preclin data
sitravatinib/beigen collabor proof
concept data nsclc rcc
sitravatiinib renal head neck
select kra inhibitor ind
sitravatinib/beigen collabor proof
concept data ovarian gastric
one oncolog
first dose patient januari current on-going dose
escal trial initi clinic data anticip either world confer
lung cancer wclc european societi medic oncolog esmo meet
report high affin kra mutat
promot clinic efficaci avoid off-target toxic preclin data yet
present peer review preclin data anticip follow
clinic data earli evid durabl respons rate higher
without unexpect toxic would substanti de-risk program
model annual base opportun patient bear
mutat lung pancreat colorect cancer potenti market
size increas efficacy/safeti profil suffici competit
warrant frontlin use ahead keytruda plu chemotherapi non-smal cell lung
oral small molecul target codon mutat specif mutat
kra protein target kra mutat similar way anaplast lymphoma
kinas epiderm growth factor receptor egfr mutat target
attempt decad sinc discoveri given kra mutat occur
human tumor frequent oncogen mutat mutat ra
famili member found human tumor kra
kra mutat particular associ poor prognosi lower respons
rate exist therapi particularli egfr-target therapi lower overal
surviv rate howev target kra histor stymi lack
recogniz bind pocket difficulti target gtp pocket kinas
likelihood widespread toxic target wild-typ kra protein
even though target kra attempt sever decad mirati one
two compani direct kra mutat inhibitor clinic enter
clinic month earlier target
mutat kra found lung adenocarcinoma colorect
carcinoma pancreat carcinoma
preclin data
clinic data
preclin data
select kra inhibitor ind
metric identifi preclin data target therapi potenc specif
efficaci durabl bioavail preclin data present mirati suggest
highli specif kra cystein moieti biochem assay
limit potenti off-target effect also abl elimin
mous pancreat tumor xenograft tumor recurr dose halt
demonstr vivo efficaci well compani suggest potenc
cell expect rang market drug preclin
project bioavail half-lif expect hour
suggest viabil once-daili oral therapi
get complet view preclin profil look forward
full present medic meet take place least
similar preclin data present rival compound
end march doctor spoken familiar data
precursor compound compani prior medic meet suggest
could concern bioavail compound pay close
attent data present caveat littl evid consid
differenti believ clean
preclin profil drug end month reflect posit
base data compani share date
phase i/ii trial design dose
escal tumor-specif expans
initi clinic trial single-arm acceler dose escal phase i/ii
trial design clinic effici trial design includ intra-pati dose
escal offer opportun enrol addit patient dose expans
cohort efficaci observ initi patient continu escal
maximum toler dose trial protocol design support single-arm
registr individu tumor expans cohort suggest mirati could
rapidli expand phase ii arm would potenti registr similar
develop novartiss dabrafenib suggest mirati could file
approv earli best-cas scenario though current assum
conserv potenti commerci entri mirati also suggest
respons rate appear similar across tumor type tumor-agnost indic
kra mutant tumor could possibl
kra data present like primari
driver share
import share present clinic data
mirati roughli four-month head start enter clinic septemb
compar mirati first dose januari mirati
suggest target septemb medic meet initi clinic data either
world congress lung cancer wclc european societi medic oncolog
esmo septemb recent guid
target mid-year first look clinic data suggest present could come
earli june would mirati present preclin data
compani expect see data patient first
present due earli natur studi main outcom anticip
earli sign respons rate least evid durabl difficult
demonstr patient drug month signific advers
event sae heavili scrutin evid off-target effect and/or
two competitor clinic think earlier present amgen
clinic data could look posit mirati two way far investor concern
success earli data would view confirmatori strategi
target kra mutat directli increas potenti similar data
would improv probabl rapid takeout follow data present
altern ideal scenario would clinic success success
produc durabl respons neg outcom appear molecule-
specif poor bioavail class effect outcom would
suggest best-in-class potenti two drug class
would like posit share
primari neg outcom clinic data present would
complet failur kra continu appear undrugg
gener even target mutat base comment
manag earlier year regard excit present data think
outcom less like posit report howev note fail
complet would anticip substanti pressur share mirati clinic
present
efficaci nsclc
target therapi oncolog egfr tradit offer
respons rate higher multipl physician expert
consult suggest due larg number signal pathway
downstream kra would predict success trial inhibitor yield
respons rate higher lower bar suggest higher likelihood
clinic success regulatori approv view barrier largest class
patient mutat lung cancer
current standard care nsclc either keytruda monotherapi keytruda plu
chemotherapi therapi provid highli signific benefit overal surviv
base assumpt success respons rate expert predict
like use second-lin therapi nsclc rather
first line assumpt still repres substanti proport potenti
patient nsclc lower estim number patient
would predict frontlin therapi
current estim potenti number patient elig therapi
estim includ nsclc
colorect cancer pancreat cancer yield efficaci
suffici supplant current frontlin standard care nsclc view
less like outcom larger base nsclc patient would expand estim total
patient elig kra therapi base-cas estim
patient guid compani primarili due model
account decreas rate lung colorect cancer report
nation cancer institut
figur credit suiss estim patient elig therapi
resist kra therapi could limit time
target kinas therapi egfr mutat typic limit
therapeut window due patient develop resist target therapi
resist typic appear within month egfr-target therapi
around month therapi physician expert consult
regard target kra expect see similar resist kra therapi doctor
also suggest due number complex signal pathway downstream
kra resist could aris earlier observ egfr
caveat mind current estim patient receiv remain
therapi month note month earli resist could reduc
time therapi current assumpt would reduc dcf
lack competitor improv market opportun
mirati current face one competitor target therapi clinic
amgen current benefit tempor advantag
enter clinic month ahead monetari advantag
develop compani greater financi resourc
physician expert expect mutation-specif inhibitor mirati
success pan-mut kra inhibitor includ sirna-
base therapi note therapi abl reach clinic take
expert opinion consider current forecast mirati
roughli split kra market fairli evenli
figur current statu kra target agent
assum follow build
probabl success
durat therapi month
estim treat patient estim patient treat
probabl unadjust repres estim
total market total kra elig patient estim divid
among follow patient assumpt
patient nsclc estim therapi
demonstr suffici respons warrant usag frontlin lung
adenocarcinoma therapi base convers physician
expert familiar kra space assum
roughli split kra popul
second-lin lung cancer anticip rapid uptak kra
target therapi post-keytruda nsclc space though expect
clinic data necessari determin compound could
market advantag
patient colorect cancer
patient pancreat cancer
colorect pancreat kra mutat
anticip frontlin use indic though low
frequenc mutat tumor type
respect sever limit market potenti
new case lung cancer predict
approx lung cancer nsclc
patient present advanced/metastat lung cancer
approx alk egfr
approx lung patient kra mutat
new case lung cancer us
patient nsclc
patient advanced/metastat lung cancer
alk-/egfr- patient elig
new case colorect cancer us
new case pancreat cancer us
patient elig second-lin therapi
durat therapi month
number dose
us revenu mm unadjust
revenu estim mirati kra program depend sever unknown
degre efficaci provid justif frontlin use kra
mutant tumor nsclc
resist kra therapi appear earlier seen
efficaci similar lung pancreat tumor patient
remain confid show clinic benefit ultim repres
approv drug howev view current kra landscap repres
peak annual opportun alon mirati potenti frontlin use
nsclc rais total market estim arena
current view fairli equival clinic
develop timelin relat potenti captur market share though
anticip addit preclin clinic data compani inform
opinion market potenti compound
current view slightli under-valued
head see kra clinic data
anticip kra clinic data either wclc esmo septemb expect
share trade short term base reaction emerg preclin data
initi clinic data strength data
drive valu overwhelm posit neg data pressur
share substanti data repres moder success consid earli
appear confirm target kra valid method treat kra
patient boost share investor gain confid target strategi
think latter scenario like caution possibl strong data
either direct pressur share
current po assumpt impli potenti upsid
success gain regulatori approv assum po base model
upsid potenti efficaci warrant frontlin use nsclc po
higher standard po phase asset due qualiti limit data
present date high potenti posit clinic data rapidli de-risk
program downsid risk program failur could see stock trade
kra highli sought-aft target oncolog sever decad mirati
one two compani directli target kra clinic recent histori
featur mutation-target oncolog therapeut loxo ignyta ariad
suggest healthi appetit asset larger oncolog compani histor
takeout premium rang clinic success kra program even
earli stage could provid substanti boost share valu
beyond compani also target kra mutat
repres larger market opportun mirati yet select lead
candid mutat ind file plan
mind current includ revenu target agent model
bring second kra target agent clinic would highli posit move
mirati would like drive share higher well
yet-to-be-select clinic agent discov
agreement array biopharma mirati owe array mid-single-digit low-double-digit
royalti sale compound along potenti
development regulatori commerci mileston program mirati guid
mileston primarili commerci heavili backload high
achiev target mirati drug discoveri platform
develop addit agent view partnership impedi
acquisit interest note loxo oncolog recent acquir
also sever key asset produc array biopharma
figur target kra continu repres signific untap
potenti oncolog
percentag cancer ra famili mutat
sitravatinibsolid base busi
limit crowd market
see sitravatinib approv nsclc like os strength interim success
multipl indic like supplement revenu base refractori
mani competitor market limit commerci opportun
sitravatinib nsclc success limit downsid potenti level
sitravatinib multi-target kinas inhibitor multi-tki target sever tyrosin
kinas receptor includ vegfr ret eph receptor famili
checkpoint-refractori nsclc addit
program checkpoint-refractori bladder cancer neoadjuv treatment renal
cell carcinoma rcc head neck cancer program sitravatinib dose
combin bristol myer opdivo nivolumab
mirati also partner beigen analysi sitravatinib combin
beigen antibodi tislelizumab nsclc rcc ovarian hepatocellular
gastric cancer sitravatinib licens beigen china australia new zealand
asia includ japan russia india mirati elig receiv
upon achiev development regulatori sale mileston plu tier royalti
rang mid-singl digit
initi phase trial sitravatinib
sitravatinib/beigen collabor proof
concept data nsclc rcc
sitravatiinib renal head neck
sitravatinib/beigen collabor proof
concept data ovarian gastric
believ sitravatinib succeed nsclc
less confid interim analysi
sitravatinib demonstr reason argument clinic signific phase ii
trial nsclc diseas control rate dcr mean three
quarter patient either stabl diseas sd partial respons pr complet
respons cr sitravatinib plu opdivo therapi howev sd
patient confirm respons yield overal
respons rate orr addit seven patient tumor
reduct exceed confirm count
toward orr estim mean durat respons month
estim progress free surviv month estim overal surviv
os month
figur sitravatinib opdivo yield impress diseas control rate
mirati announc plan studi design phase registr trial os
primari endpoint sitravatinib/opdivo combin test
compar arm featur chemotherapi docetaxel physician expert poll
suggest os greater six month could suffici approv
os seen docetaxel trial typic around six month consid high dor
os rate observ sitravatinib plu opdivo phase ii see combin
like beat docetaxel os approv current assign po sitravatinib
nsclc standard po asset phase clinic trial mirati expect
data primari analysi near end
docetaxel could difficult compar
mirati built interim analysi nsclc phase trial method appli
acceler approv trial on-going use orr interim readout
compani express confid success interim analysi highlight
docetaxel low orr prior trial antibodi suggest orr
low could statist succeed
howev doctor spoken note start see
better respons docetaxel checkpoint refractori popul
observ histor late-lin nsclc expert estim checkpoint refractori
patient docetaxel could show orr closer rather
observ checkpoint-nav patient howev retrospect analys reveal
increas respons rate like translat benefit os
believ potenti interim analysi succeed much lower
success primari os analysi base discuss doctor believ
predict respons rate close report orr sitravatinib plu opdivo
consid interim analysi anticip late failur interim would
delay mirati abil file regulatori approv least month reduc
compani head start becom first new checkpoint refractori therapi nsclc
import note concern time commerci launch
clinic success skeptic success interim analysi
maintain po primari analysi succeed standard
assumpt po phase asset due low bar success os
addit indic may offer potenti upsid
beyond nsclc sitravatinib plu opdivo combin current examin
sever phase ii studi success would help diversifi revenu base
bladder cancer sitravatinib/opdivo combin test single-arm
patient trial treat advanced/metastat urotheli carcinoma patient whose
recent treatment checkpoint inhibitor patient need refractori
tki although assum patient due frontlin use tki
set initi proof-of-concept data expect
rcc sitravatinib plu opdivo test neoadjuv therapi prior surgeri
patient local advanc rcc prior partial complet nephrectomi earli
proof-of-concept data single-arm trial expect
current assum po trial bladder cancer rcc in-lin
standard assumpt phase ii asset
head neck sitravatinib plu opdivo also test neoadjuv therapi
investigator-initi trial studi therapi prior surgeri remov
squamou cell carcinoma oral caviti singl arm trial
perform mirati rather univers health network toronto
compani control execut though clinicaltri gov suggest data may
avail late
due outsid natur investigator-initi trial lack involv
compani includ revenu head neck sitravatinib
model time
beigen collabor beigen fund conduct sever combin trial
sitravatinib inhibitor tislelizumab trial examin
combin checkpoint-nav -refractori patient five tumor type
nsclc rcc nave refractori checkpoint nave
ovarian gastric cancer initi proof-of-concept data nsclc rcc
portion collabor expect data remain
indic anticip
collabor repres intrigu potenti gener revenu
emerg market also expand clinic profil sitravatinib without
incur addit expens includ possibl justif target
lucr front-lin lung market current includ collabor mileston
revenu model due low volum data compar tislelizumab
current approv antibodi includ addit sale royalti
revenu model time
mutat mirati test single-ag sitravatinib patient loss-of-
function mutat casita b-lineag lymphoma phase ib exploratori
studi last report compani confirm two patient partial
respons single-ag sitravatinib await data program
includ revenu cbl-mutat patient model
lenvatinib
nsclc rcc
sitravatinib like face number competitor checkpoint refractori market
within class multi-tki primarili wide array experiment
immuno-oncolog io compound target immun system fight tumor
beyond antibodi variou mechan
competit tki unlik
sitravatinib behind bladder
within multi-tki famili sitravatinib compet exelixis/ipsen cabometyx
cabozantinib astrazeneca/merck lenvima
closest
contemporari multi-target kinas inhibitor market
sitravatinib hold substanti lead competitor nsclc far
lucr potenti indic cabozantinib lenvatinib studi phase
ib expans trial sitravatinib prepar initi phase trial second
quarter suggest sitravatinib would like two- three-year head
start competitor field merck recent initi phase trial studi
keytruda /- lenvima howev trial frontlin patient anticip
success market entri would result competit sitravatinib/opdivo combin
second-lin therapi
cabozantinib current studi phase ii expans trial bladder cancer
present promis earli data phase ib cohort
see proof-of-concept data sitravatinib indic estim
cabozantinib could one- two-year head start market lenvatinib also
studi bladder cancer combin keytruda though initi proof-of-
concept data combin yet present new phase ii trial examin
cabozantinib plu keytruda frontlin bladder cancer launch last fall though
believ frontlin trial competit use sitravatinib second line
rcc note cabozantinib lenvatinib alreadi approv treat
advanced/metastat rcc also studi frontlin advanced/metastat
rcc combin opdivo cabozantinib keytruda lenvatinib
said approv clinic trial neoadjuv set
provid competit blockad neoadjuv patient howev monotherapi
current test neoadjuv adjuv set
monotherapi sitravatinib plu opdivo combin succeed
respect neoadjuv rcc clinic trial sitravatinib combo would need show
ad benefit cross-trial comparison doctor justifi ad cost toxic
monotherapi set reason assum monotherapi gain
market share sitravatinib combin therapi
figur comparison sitravatinib multi-tki
next-gener agent like crowd market
competit appear limit contemporari multi-tki potenti
competit much higher burgeon next-gener immuno-oncolog
market breviti sake list everi potenti agent could provid
competit sitravatinib nsclc bladder rcc therapi
howev non-comprehens list target investig nsclc alon
either current soon plan phase ii phase clinic trial il-
toll-lik receptor complement receptor adenosin receptor and/or
well non-io agent antibody/drug conjug adc parp
agent also pair therapi
doctor poll optimist new therapi
agre target excit agre see
monotherapi efficaci import reduc toxic cost patient mani
agent target new target test monotherapi
sole combin agent see sitravatinib combo like use
less new monotherapi enter market
natur mani therapi unlik reach commerci stage sheer
number on-going trial suggest us sever therapi like succeed
though sitravatinib well posit gain earli market share succeed
interim analysi lung cancer trial view larg number potenti competitor
nsclc could potenti gain acceler approv phase ii trial
formid roadblock sitravatinib build maintain domin market posit
assum follow sitravatinib build
probabl success nsclc bladder neoadjuv rcc
durat therapi month nsclc bladder two month neoadjuv
estim treat patient estim patient treat
sitravatinib probabl unadjust estim total market elig
patient indic estim divid among follow patient
patient nsclc bladder due expect
crowd market place anticip broad use sitravatinib
checkpoint-refractori nsclc patient though could rapid uptak
sitravatinib succeed interim endpoint gain acceler
regulatori approv predict upcom io combin limit market
uptak particularli io agent display efficaci monotherapi
patient neoadjuv rcc estim
nephrectomi patient receiv neoadjuv therapi believ
sitravatinib combin opdivo face stiff competit
antibodi monotherapi set howev forecast eight
week therapi neoadjuv set expect neoadjuv
therapi larg impact sitravatinib revenu
figur sitravatinib revenu build nsclc probabl unadjust
new case lung cancer predict
approx lung cancer nsclc
patient present advanced/metastat lung cancer
approx alk egfr
approx patient posit
new case lung cancer us
patient nsclc
patient advanced/metastat lung cancer
alk-/egfr- patient elig
patient elig second-lin therapi
io mono combin therapi
durat sitravatinib therapi month
number dose sitravatinib
revenu estim mirati sitravatinib program depend sever unknown
respons rate sitravatinib plu opdivo significantli outperform could
higher-than-anticip respons rate compar arm docetaxel
though expect sitravatinib plu opdivo outperform docetaxel orr
endpoint would shift sitravatinib
commerci earlier improv market penetr
interim analysi success
number compet therapi checkpoint refractori
popul succeed gain regulatori approv quickli could
commerci sitravatinib combo therapi compar efficaci
safeti profil emerg therapi
anticip sitravatinib demonstr efficacy/tox profil
consid best class compar emerg therapi second-
line lung cancer howev expect failur approv io therapi
emerg come month would requir upward revis
sitravatinib expect price in-lin compar multi-tki cabometyx
lenvima current wholesal acquisit cost wac cabometyx
lenvima consid likelihood price
inflat assum commerci launch estim
sitravatinib launch list price anticip competit market
sitravatinib estim gross-to-net discount yield net launch price
mirati suggest price in-lin current tki
offer tagrisso like comp price current wac price tagrisso
given sever year estim price inflat expect launch
list price due low-competit environ anticip
kras-target agent estim gross-net discount
yield net launch price
model cash flow sitravatinib anticip loss
exclus follow expir composit matter patent expir plu
assum grant standard hatch-waxman five-year extens model cash
flow anticip loss exclus
current expect launch commerci year prior patent expir
anticip extens grant hatch-waxman total revenu compound-annual-growth-rate
target price determin use split product-bas
revenu dcf valuat dcf dcf model base discount rate
product fulli dilut share million long-term oper
margin tax rate probability-adjust model assign
valu sitravatinib valu kra program assign valu
pipelin revenu termin valu
detail dcf compon includ follow
dcf-deriv valu repres potenti base
increas revenu decreas sg would expect
acquisit occur clinic data present
forecast assign valu sitravatinib
howev base recent histori trade past six month
believ investor current ad equal weight kra program
valuat would anticip failur either program would result loss
share price
compani cash cash equival end-decemb
addit rais januari mirati current hold cash cash
equival anticip mirati need rais cash sever time
commerci launch howev also anticip posit free cash flow ep
begin
blue sky scenario valu reflect po sitravatinib lung
grey sky scenario valu reflect
po sitravatinib lung po kra program
clinic regulatori risk includ limit trial enrol delay poorli
design studi inadequ endpoint enough statist power neg
efficaci and/or safeti data neg decisions/rul regulatori author
failur sitravatinib phase trial nsclc demonstr improv os
emerg previous unseen safeti issu sitravatinib
failur kra asset establish poc
failur sitravatinib establish poc addit indic
financi mismanag lead liquidity/fund difficulti pipelin asset
manufactur suppli risk includ limit suppli disrupt product
batch adher qualiti standard batch contamin technic difficulti
complex molecul delay construction/certif new facil failur
sitravatinib suppli interrupt global clinic trial
commerci risk includ limit lower-than-expect adopt drug
target popul stronger-than-anticip competit drug establish
market competit clinical-stag asset failur achiev formulari statu
payor-impos access restrict drug price reform lead price restrict
posit updat competitor multi-tki and/or immuno-oncolog space
aggress competit limit market share
slower-than-anticip adopt rate market therapi
early-stag biotechnolog compani often need rais addit capit fund
clinic develop drug candid depend time market condit may
advers could limit access capit result unfavor term base
current project suffici cash cash equival fund oper
research develop expens
sell gener administr expens
profit loss tax
cash equival
prepaid expens current asset
properti equip net
commit conting
amort debt discount
loss/ dispos fix asset
chang asset liabil
prepaid expens asset
net cash use oper activ
purchas properti equip
sale ppe
purchas invest
sale/matur invest
net cash use invest activ
proce issuanc debt
proce exercis stock option
proce issuanc prefer stock net issuanc cost
proce issuanc common stock net
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
compani mention price
